Sfoglia per AUTORE
POUR L
Collezione AOU Città della Salute di Torino

  

Items : 9

A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma. in EJHaem / EJHaem. 2024 Aug 1;5(5):940-950. doi: 10.1002/jha2.968. eCollection 2024 Oct.

2024
AOU Città della Salute di Torino

Legenne P; Zitt C; Dawson KM; Stumpp MT; Suter C; Pour L; Iversen KF; Gamberi B; Khandanpour C; Vacca A; Jurczyszyn A; Trautmann-Grill K; Bringhen S; Grz??ko N; Szarejko M; Knop S; Stavropoulou V; Fey MF; Leupin N; Goldschmidt H;

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. in The Lancet. Oncology / Lancet Oncol. 2023 Oct;24(10):1119-1133. doi: 10.1016/S1470-2045(23)00405-9. Epub 2023 Sep 14.

2023
AOU Città della Salute di Torino

Benjamin R; Hájek R; Zweegman S; Silkjaer T; Caers J; Mancuso K; Tacchetti P; Razawy W; Grasso M; Giaccone L; Offidani M; Lund T; van der Velden VHJ; Pour L; Gadisseur A; Pietrantuono G; Broijl A; Roeloffzen WWH; Wu KL; Schjesvold F; van der Holt B; Minnema MC; van de Donk NWCJ; Vangsted AJ; Boccadoro M; Gay F; Sonneveld P; Musto P;

Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study. in Clinical lymphoma, myeloma & leukemia / Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):491-504. doi: 10.1016/j.clml.2023.03.007. Epub 2023 Mar 2

2023
AOU Città della Salute di Torino

Cain LE; Manne S; Rajkumar SV; Cherepanov D; Wang B; Vorog A; Labotka RJ; C de Farias DL; Min CK; Grosicki S; Benjamin R; Pour L; Bringhen S; Dimopoulos MA;

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma. in HemaSphere / Hemasphere. 2022 Sep 30;6(10):e786. doi: 10.1097/HS9.0000000000000786. eCollection 2022 Oct.

2022
AOU Città della Salute di Torino

Sonneveld P; Zweegman S; Cavo M; Nasserinejad K; Broijl A; Troia R; Pour L; Croockewit S; Corradini P; Patriarca F; Wu K; Droogendijk J; Bos G; Hajek R; Teresa Petrucci M; Ypma P; Zojer N; Minnema MC; Boccadoro M;

Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2021 Nov 10;39(32):3613-3622. doi: 10.1200/JCO.21.01045. Epub 2021 Sep 14.

2021
AOU Città della Salute di Torino

Sonneveld P; Dimopoulos MA; Beksac M; van der Holt B; Aquino S; Ludwig H; Zweegman S; Zander T; Zamagni E; Wester R; Hajek R; Pantani L; Dozza L; Gay F; Cafro A; De Rosa L; Morelli A; Gregersen H; Gulbrandsen N; Cornelisse P; Troia R; Oliva S; van de Velden V; Wu K; Ypma PF; Bos G; Levin MD; Pour L; Driessen C; et alii...

Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. in Leukemia research / Leuk Res. 2021 May;104:106576. doi: 10.1016/j.leukres.2021.106576. Epub 2021 Mar 29.

2021
AOU Città della Salute di Torino

Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG;

Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. in Journal of clinical medicine / J Clin Med. 2020 Sep 27;9(10):3120. doi: 10.3390/jcm9103120.

2020
AOU Città della Salute di Torino

Mateos MV; Bladé J; Bringhen S; Ocio EM; Efebera Y; Pour L; Gay F; Sonneveld P; Gullbo J; Richardson PG;

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. in The Lancet. Haematology / Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.

2020
AOU Città della Salute di Torino

Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; et alii...

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17.

2015
AOU Città della Salute di Torino

Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A;